ClinicalTrials.gg
RecruitingNCT05793749Updated Mar 31, 2023

Early Intervention to Prevent Lower Limb Lymphedema of Gynecological Malignancy

An interventional study of Prophylactic lymphedema treatment in Uterine Cervical Neoplasms, Endometrial Neoplasms and Lymphedema, sponsored by Chongqing University Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Chongqing University Cancer Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital — 13 open to participants now, 13 under way, none of them phase 3. Uterine Cervical Neoplasms · Chongqing University Cancer Hospital.

Planned enrollment
3rd of 15
400 · median 60
Started
2023
with 4 others
No phase
9 of 18
8 open now
Primary completion
2026-07
later than 5 of 12 live
Registered
8th of 18
by date

Among the 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 8th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

13 of the 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Uterine Cervical Neoplasms by Chongqing University Cancer Hospital, or all of them as a file.
02

Study summary

This study is a prospective, randomized, controlled clinical trial of a single center in China and plans to enroll 400 patients.

  1. Patients with diagnosed gynecological malignancies who underwent pelvic and abdominal lymphadenectomy and required pelvic radiotherapy;
  2. Random grouping (A:B=3:1): A. Prophylactic lymphoedema treatment; B. Standard care group;
  3. Preventive lymphedema health education was given to patients with gynecological malignant tumors without contraindications before surgery. All patients were randomly divided into an intervention group and a nonintervention group. The intervention group received preventive lymphedema treatment twice a week. 10 times, and the interval between the two treatments was not less than 48 hours and not more than 2 weeks. The intervention measures included four parts: manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings. In the nonintervention group, knowledge education and telephone follow-up were routinely conducted.
  4. All patients were evaluated for edema, lymphedema symptoms and quality of life 1 day before radiotherapy, every Friday during radiotherapy and every 3 months thereafter. Bioelectrical impedance measurement and leg diameter measurement were used to evaluate edema, the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) was used to evaluate lymphedema symptoms, and the EORTC Quality of Life Scale (QLQ-C30) was used to evaluate quality of life. followed up to 2 years after the end of lymphedema prophylaxis.
Read the detailed description

Research background Gynecological malignancies, including cervical cancer, ovarian cancer, endometrial cancer, vulvar cancer, etc., are important diseases threatening women's health worldwide, and their main treatment methods are surgery and radiotherapy. During surgery, different numbers of lymph nodes are removed, and lymphatic fluid and tissue exudate from the stump lymphatic vessels accumulate, causing disruption of the original lymphatic circulation and obstruction of lymphatic fluid return, which leads to lower limb edema . The longer the radiotherapy lasts, the more serious the phenomenon of collateral circulation will be, and the lymphatic return pathway will be damaged, resulting in lower limb lymphedema .

Lower extremity lymphedema is a relatively common complication after treatment for gynecologic malignancies, and it has been reported that approximately 20 million patients worldwide are affected by lower extremity lymphedema. The overall incidence of lower extremity lymphedema after gynecologic malignancy treatment is about 25% and can be as high as 70% in special groups . Age, weight, radiotherapy dose, duration of postoperative radiotherapy, tumor stage, daily standing time, number of lymph node dissection, and co-infection are all risk factors for the occurrence of lower extremity lymphedema.

Lymphedema is characterized by sunken edema at the beginning of the disease and progresses to include swelling, numbness, heaviness, tissue fibrosis, impaired movement, and rough epidermal keratinization, and increases the risk of inflammation of the lymphatic vessels and surrounding tissues and cellulitis. Lower extremity lymphedema is a chronic progressive disease that is difficult to cure and has a negative impact on limb function, daily life, quality of life and psychological well-being.

The treatment of lymphedema includes surgical treatment and conservative treatment. The conservative treatment methods include Complex Decongestion Therapy (CDT), external application of Chinese herbal medicine and western medicine, etc. The Complex Decongestion Therapy (CDT) is the most widely used lymphedema treatment with the best efficacy internationally in recent years. The treatment method, but requires long-term or even lifelong care , which brings huge psychological burden and economic pressure to the patient's family. Therefore, lymphedema of the lower extremities should be prevented, and preventive and therapeutic measures should be taken as early as possible to improve the quality of life of patients.

Currently, studies on lymphedema prevention have focused on interventions for breast cancer-related lymphedema , while few studies have been reported on the prevention of lymphedema associated with gynecologic malignancies. Research reported that early intervention with freehand lymphatic drainage technique could effectively prevent lower limb lymphedema, and Research showed that full range of hip exercises could prevent lower limb lymphedema after cervical cancer surgery, in addition, some studies also found that freehand lymphatic drainage combined with Kegel training could prevent vulvar stage I lymphedema after cervical cancer surgery, however, these studies have some limitations, such as small sample size and limited study content. However, these studies have limitations, such as small sample size and limited study content. Moreover, there are no empirical studies on the prevention of lower extremity lymphedema in large samples, and there is no unified standard for the prevention and management of lower extremity lymphedema. Therefore, in this study, the investigators used an evidence-based approach and clinical experience to conduct a prospective study on the prevention of lower limb lymphedema in order to reduce the incidence of lower limb lymphedema, improve patients' quality of life, and reduce their economic burden.

Research objective

  1. To understand the incidence of lymphedema after gynecological tumor surgery and radiotherapy and its impact on the quality of life of patients.
  2. Through preventive lymphedema treatment intervention, reduce the proportion of lymphedema, reduce the economic burden of patients, and improve their quality of life.
  3. We aimed to find a more economical and effective method to treat gynecological malignant tumor lymphedema.

Main outcome measures: The incidence of lower extremity lymphedema after gynecological cancer surgery and radiotherapy, and the incidence of lower extremity lymphedema after prophylactic lymphedema treatment.

Secondary outcome measures: quality of life, incidence of lymphedema symptoms, and progression-free survival (PFS).

Study population

Inclusion criteria:

  1. Gynecologic oncology patients undergoing radiotherapy after lymph node surgery who voluntarily participate in this study and sign an informed consent form.
  2. 18 to 60 years old.
  3. Eastern Cooperative Oncology Group(ECOG) score less than 2.
  4. Expected survival time greater than 3 years.
  5. Hemoglobin(Hb) greater than or equal to 70 g/L, white blood cells (WBC)greater than or equal to 3.5 × 109 /L, neutrophils(ANC)greater than or equal to 1.5 × 109 /L, platelets (PLT)greater than or equal to 80 × 109 /L.
  6. serum alamine aminotransferase(ALT) and glutamic oxalacetic transaminase(AST) less than 2 times the normal value and creatinine less than 1.5 times the normal value, albumin greater than or equal to 35g/L.
  7. Women of childbearing potential must have had a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and be willing to use an appropriate method of contraception for the duration of the trial.
  8. Ability to comply with the trial protocol, as judged by the investigator.

Exclusion criteria:

  1. Lymphedema and deep vein thrombosis of the lower extremities were clearly diagnosed;
  2. Acute infection of any kind;
  3. Patients with lower extremity edema;
  4. pregnancy, menstrual period;
  5. Recent major abdominal surgery (determined by the investigator);
  6. Radiation colitis, cystitis, intestinal infection, small bowel or large bowel diverticulitis or diverticulitis;
  7. Liver fibrosis;
  8. Abdominal aortic aneurysm;
  9. acute phlebitis;
  10. Severe arterial obstructive disease, arterial ulcer, ABPI (ankle-brachial blood pressure index) greater than 1.3 and less than 0.5;
  11. Severe peripheral neuropathy;
  12. Poor control of hypertension, poor control of stroke and diabetes, and severe bronchial asthma;
  13. Patients who cannot understand the experimental content and cannot cooperate and those who refuse to sign the informed consent;
  14. Those with concomitant diseases or other special circumstances that seriously endanger the patient's safety or affect the patient's completion of the study.

Subject Termination Criteria

  1. The investigator believes that the treatment should be terminated from the perspective of the best benefit of the patients;
  2. There are intolerable adverse reactions, after confirmation by the investigator;
  3. Failure to complete the treatment according to the cycle and time;
  4. The patient withdraws informed consent.

Elimination criteria:

(1) Those who did not meet the standards and were mistakenly included.

03

Conditions studied

  • Uterine Cervical Neoplasms
  • Endometrial Neoplasms
  • Lymphedema
  • Treatment Effectiveness

Keywords

  • Lymphedema
  • Endometrial Neoplasms
  • Uterine Cervical Neoplasms
  • Treatment Effectiveness
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.Gynecologic oncology patients undergoing radiotherapy after lymph node surgery who voluntarily participate in this study and sign an form.

2.18 to 60 years old. 3.(ECOG) score less than 2. 4.Expected survival time greater than 3 years. 5.(Hb) greater than or equal to 70 g/L, white blood cells (WBC)greater than or equal to 3.5 × 109 /L, neutrophils(ANC)greater than or equal to 1.5 × 109 /L, (PLT)greater than or equal to 80 × 109 /L.

6.serum alamine aminotransferase() and glutamic oxalacetic transaminase(AST) less than 2 times the normal value and creatinine less than 1.5 times the normal value, albumin greater than or equal to 35g/L.

7.Women of must have had a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and be willing to use an appropriate method of for the duration of the trial.

8.Ability to comply with the trial protocol, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Lymphedema and deep vein thrombosis of the lower extremities were clearly diagnosed;
  2. Acute infection of any kind;
  3. Patients with lower extremity edema;
  4. pregnancy, menstrual period;
  5. Recent major abdominal surgery (determined by the investigator);
  6. Radiation colitis, cystitis, intestinal infection, small bowel or large bowel diverticulitis or diverticulitis;
  7. Liver fibrosis;
  8. Abdominal aortic aneurysm;
  9. acute phlebitis;
  10. Severe arterial obstructive disease, arterial ulcer, ABPI (ankle-brachial blood pressure index) greater than 1.3 and less than 0.5;
  11. Severe peripheral neuropathy;
  12. Poor control of hypertension, poor control of stroke and diabetes, and severe bronchial asthma;
  13. Patients who cannot understand the experimental content and cannot cooperate and those who refuse to sign the ;
  14. Those with concomitant diseases or other special circumstances that seriously endanger the patient's safety or affect the patient's completion of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Prophylactic lymphedema treatment

    Prophylactic lymphedema treatment:The lymphedema prophylaxis treatment consists of four parts:manual lymphatic drainage, skin care, functional exercise, and wearing lymphedema preventive compression stockings. The prophylactic lymphedema treatment group receives lymphedema prophylaxis twice a week for a total of 10 sessions, each requiring an interval of at least 48 hours but no more than 2 weeks.

    Behavioral: Prophylactic lymphedema treatment

  • No intervention
    Standard of care

    Standard of care,includeIn knowledge education and telephone follow-up were routinely conducted.

Interventions

  • BehavioralProphylactic lymphedema treatment

    1. perform manual lymphatic drainage twice a week after the start of radiotherapy for a total of 10 times, and wear lymphedema compression stockings after each manual lymphatic drainage, 2. teach patients how to care for their skin. 3. perform functional exercises for lymphedema of the lower extremities twice a day for 15 \~ 20 minutes each time. 4. follow up observation: before the start of radiotherapy, every Friday during radiotherapy, and every 3 months after the end of radiotherapy, the occurrence of lymphedema and related symptoms and quality of life were evaluated.

06

What researchers measure

Primary outcomes

  1. Incidence of lymphedema

    The incidence of lower extremity lymphedema after gynecological cancer surgery and radiotherapy, and the incidence of lower extremity lymphedema after prophylactic lymphedema treatment.

    Time frame: Incidence of lymphedema in the prophylactic lymphedema treatment group and the standard treatment group at 2 years after the end of radiotherapy

  2. Quality of life of patients

    The quality of life of cancer patients (QLQ-C30) was used to assess the quality of life of patients. Including the overall quality of life subscale, functional subscale, symptom subscale, and individual test items. The higher the overall quality of life subscale and the functional subscale score, the better the quality or function. The more severe the symptoms.

    Time frame: Quality of life QLQ-C30 scores for the prophylactic lymphedema treatment group and the standard treatment group at 2 years after the end of radiotherapy

Secondary outcomes

  1. Subjective feelings

    The Gynecologic Cancer Lymphedema Questionnaire (GCLQ) was used to evaluate the subjective feelings of patients, which was mainly used to evaluate whether the limbs had symptoms such as swelling, pain, and heaviness. The evaluation included 7 symptom groups of heaviness, edema (overall), swelling (local), infection-related symptoms, pain, numbness, and limb function, with a total of 20 items.1 mark for "yes" and 0 mark for "no" for each entry. The higher the GCLQ score, the worse the subjective perception, and a score greater than or equal to 4 is recognized as the onset of lymphedema.

    Time frame: Quality of life GCLQ scores for the prophylactic lymphedema treatment group and the standard treatment group at 2 years after the end of radiotherapy

  2. 2-year progression-free survival,2-year PFS

    2-year PFS was defined as the time from randomization to the first occurrence of disease progression or death from any cause within 2 years

    Time frame: 2-year PFS was defined as the time from randomization to the first occurrence of disease progression or death from any cause within 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38. doi: 10.1007/s00280-017-3501-8. Epub 2017 Dec 16. PubMed 29249039 ↗
  • Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol. 2018 Mar;148(3):609-621. doi: 10.1016/j.ygyno.2018.01.009. Epub 2018 Feb 3. PubMed 29666026 ↗
  • 李可心,孙洪赞,辛军,等.早期宫颈癌盆腔淋巴结转移危险因素及PET/CT诊断[J].中国医学影像技术,2018,34: 265-269.
  • 朱认真,张开宇,李倩.宫颈癌术后放疗致下肢淋巴水肿及神经电生理功能的影响及机制分析[J]. 实用癌症杂志, 2020,35: 121-124
  • Dessources K, Aviki E, Leitao MM Jr. Lower extremity lymphedema in patients with gynecologic malignancies. Int J Gynecol Cancer. 2020 Feb;30(2):252-260. doi: 10.1136/ijgc-2019-001032. Epub 2020 Jan 7. PubMed 31915136 ↗
  • Jiang X, Nicolls MR, Tian W, Rockson SG. Lymphatic Dysfunction, Leukotrienes, and Lymphedema. Annu Rev Physiol. 2018 Feb 10;80:49-70. doi: 10.1146/annurev-physiol-022516-034008. Epub 2017 Oct 13. PubMed 29029593 ↗
  • 张赫,孔为民.宫颈癌治疗后下肢淋巴水肿预防进展[J].国际妇产科学杂志,2021,48(02):139-143.
  • Fukushima T, Tsuji T, Sano Y, Miyata C, Kamisako M, Hohri H, Yoshimura C, Asakura M, Okitsu T, Muraoka K, Liu M. Immediate effects of active exercise with compression therapy on lower-limb lymphedema. Support Care Cancer. 2017 Aug;25(8):2603-2610. doi: 10.1007/s00520-017-3671-2. Epub 2017 Apr 6. PubMed 28386788 ↗
  • 中华整形外科学分会淋巴水肿学组.外周淋巴水肿诊疗的中国专家共识[J].中华整形外科杂志,2020,36(4):355-360.
  • 梁笑媚,黄伟斌.腋窝反向淋巴作图预防乳腺癌术后上肢水肿的预防应用研究[J].中国卫生标准管理,2021.12(15):58-60.
  • 白巧玲,王星.宫颈癌术后早期徒手淋巴引流预防术后下肢淋巴水肿[J].现代肿瘤医学,2021,29(19):3440-3442.
  • Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecol Oncol. 2010 May;117(2):317-23. doi: 10.1016/j.ygyno.2010.01.022. Epub 2010 Feb 16. PubMed 20163847 ↗
  • Taarnhoj GA, Kennedy FR, Absolom KL, Baeksted C, Vogelius IR, Johansen C, Velikova G, Pappot H. Comparison of EORTC QLQ-C30 and PRO-CTCAE Questionnaires on Six Symptom Items. J Pain Symptom Manage. 2018 Sep;56(3):421-429. doi: 10.1016/j.jpainsymman.2018.05.017. Epub 2018 May 25. PubMed 29807157 ↗

Individual participant data

Plan to share: No — This study is a prospective, randomized, controlled clinical trial of a single center in China and plans to enroll 400 patients. 1.Patients with diagnosed gynecological malignancies who underwent pelvic and abdominal lymphadenectomy and required pelvic radiotherapy. 2.Random grouping (A:B=3:1). 3.Preventive lymphedema health education was given to patients with gynecological malignant tumors without contraindications before surgery. 4.All patients were evaluated for edema, lymphedema symptoms and quality of life ,Bioelectrical impedance measurement and leg diameter measurement , the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) , and the EORTC Quality of Life Scale (QLQ-C30) will be used

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2023; primary completion for Jul 2026, 39 months later.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 39 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2022
First posted
Mar 31, 2023
StartEst.
Apr 1, 2023
Primary completionEst.
Jul 29, 2026
CompletionEst.
Jul 29, 2026
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05793749
Lead sponsor
Chongqing University Cancer Hospital
Responsible party
Dongling Zou (professor,Doctor, Chongqing University Cancer Hospital) — Principal investigator
First posted
Mar 31, 2023
Start date
Apr 1, 2023 (estimated)
Primary completion
Jul 29, 2026 (estimated)
Completion
Jul 29, 2026 (estimated)
Last update
Mar 31, 2023

Study contacts

Dongling Zou, Doctor
Contact
cqzl_zdl@163.com
+8613657690699

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion